Israele - ebraico - Ministry of Health

abbvie biopharmaceuticals ltd, israel - risankizumab - תמיסה להזרקה - risankizumab 150 mg/ml - risankizumab

Israele - ebraico - Ministry of Health

abbvie biopharmaceuticals ltd, israel - risankizumab - תרכיז להכנת תמיסה לאינפוזיה - risankizumab 60 mg/ml - risankizumab

Israele - ebraico - Ministry of Health

abbvie biopharmaceuticals ltd, israel - upadacitinib as hemihydrate - טבליות בשחרור ממושך - upadacitinib as hemihydrate 45 mg - upadacitinib

Israele - ebraico - Ministry of Health

abbvie biopharmaceuticals ltd, israel - foscarbidopa; foslevodopa - תמיסה לאינפוזיה - foslevodopa 240 mg / 1 ml; foscarbidopa 12 mg / 1 ml

Israele - ebraico - Ministry of Health

abbvie biopharmaceuticals ltd, israel - leuprorelin acetate 3.75 mg/vial - suspension for injection - leuprorelin - endometriosis prostatic cancer treatment of uterine fibroids for a period of up to six months. treatment of breast cancer in pre- and peri - menopausal women in whom hormone therapy is specified.

Israele - ebraico - Ministry of Health

abbvie biopharmaceuticals ltd, israel - leuprorelin acetate 11.25 mg - powder for suspension for injection - leuprorelin - endometriosis prostatic cancer treatment of uterine fibroids for a period of up to six months. treatment of breast cancer in pre- and peri - menopausal women in whom hormone therapy is specified.

Israele - ebraico - Ministry of Health

abbvie biopharmaceuticals ltd, israel - ciclosporin - תחליב לעין - ciclosporin 0.05 % - cyclosporin - cyclosporin - to increase tear production in patients whose tear production is presumed to be supressed due to ocular inflammation associated with keratoconjunctivitis sicca. increased tear production was not seen in patients currently taking topical anti-inflammatory drugs or using punctal plugs.

Israele - ebraico - Ministry of Health

abbvie biopharmaceuticals ltd, israel - botulinum toxin type a - אבקה להכנת תמיסה לזריקה - botulinum toxin type a 100 u/vial - botulinum toxin - botulinum toxin - botox is indicated for the symptomatic relief of blepharospasm or vii nerve disorders in patients over 12 years hemifacial spasm and associated focal dystonias as well as the correction of strabismus in patients 12 years of age and above. botox is also indicated for the reduction of the signs and symptoms of spasmodic torticollis ( cervical dystonia) in adults. botox is also indicated for the treatment of dynamic equinus foot deformity due to spasticity in paediatric cerebral palsy patients two years of age or older. focal upper limb spasticity associated with stroke. botox is indicated also for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients aged 65 years or less. management of primary axillary hyperhidrosis in patients who failed other medical symptomatic treatment.symptom relief in adults fulfilling criteria for chronic migraine (headaches on ?15 days per month of which at least 8 days with migrai

Israele - ebraico - Ministry of Health

abbvie biopharmaceuticals ltd, israel - botulinum toxin type a - אבקה להכנת תמיסה לזריקה - botulinum toxin type a 50 u/vial - botulinum toxin - botulinum toxin - botox is indicated for the symptomatic relief of blepharospasm or vii nerve disorders in patients over 12 years hemifacial spasm and associated focal dystonias as well as the correction of strabismus in patients 12 years of age and above. botox is also indicated for the reduction of the signs and symptoms of spasmodic torticollis ( cervical dystonia) in adults. botox is also indicated for the treatment of dynamic equinus foot deformity due to spasticity in paediatric cerebral palsy patients two years of age or older. focal upper limb spasticity associated with stroke. botox is indicated also for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients aged 65 years or less. management of primary axillary hyperhidrosis in patients who failed other medical symptomatic treatment.symptom relief in adults fulfilling criteria for chronic migraine (headaches on ?15 days per month of which at least 8 days with migrai

Israele - ebraico - Ministry of Health

abbvie biopharmaceuticals ltd, israel - botulinum toxin type a - אבקה להכנת תמיסה לזריקה - botulinum toxin type a 200 u/vial - botulinum toxin - botulinum toxin - botox is indicated for the symptomatic relief of blepharospasm or vii nerve disorders in patients over 12 years hemifacial spasm and associated focal dystonias as well as the correction of strabismus in patients 12 years of age and above. botox is also indicated for the reduction of the signs and symptoms of spasmodic torticollis ( cervical dystonia) in adults. botox is also indicated for the treatment of dynamic equinus foot deformity due to spasticity in paediatric cerebral palsy patients two years of age or older. focal upper limb spasticity associated with stroke. botox is indicated also for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients aged 65 years or less.management of primary axillary hyperhidrosis in patients who failed other medical symptomatic treatment.symptom relief in adults fulfilling criteria for chronic migraine (headaches on ?15 days per month of which at least 8 days with migrain